QRxPharma has executed a licensing agreement with Aspen Pharmacare for the commercialisation rights to immediate-release (IR) MoxDuo (morphine+oxycodone) in South Africa.
On September 11, QRxPharma announced a licensing deal with Aspen's Australian subsidiary for the Australia, New Zealand and Oceania commercialisation rights to IR MoxDuo. That agreement also provided Aspen an option to enter into a licence for the territory of South Africa, which Aspen has now exercised.
Under the licensing agreement, Aspen will receive the exclusive rights to commercialise IR MoxDuo in South Africa and will assume responsibility for the regulatory filing, all product launch costs as well as ongoing marketing and sales efforts. QRxPharma will receive a AUD 250,000 milestone payment upon regulatory approval of IR MoxDuo in South Africa, together with double-digit royalties on all sales. QRxPharma retains all rights to the intravenous and controlled-release formulations of MoxDuo in South Africa.
In Q413, QRxPharma plans to refile with the FDA an NDA for IR MoxDuo for the treatment of acute pain. QRxPharma has entered into strategic collaborations with Actavis (in December 2011), Paladin Labs (in October 2012) and Aspen for the commercialisation of IR MoxDuo in the US, Canadian, Australian (including New Zealand and Oceania) and South African acute pain markets respectively.
|Agreement Status:||Updated||Date Announced:||15 Oct 2013|
|Date Last Reported:||11 Sep 2013||Duration:|
|Est Total Value:||Investment To Date:|
|Generic / Brand Name:||MoxDuo morphine oxycodone|
|Therapeutic Area:||Central Nervous System|